Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Revisiting asthma control: how should it best be defined?

Nicola A Hanania1

  • 1Pulmonary and Critical Care Medicine, Asthma Clinical Research Center, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, USA. hanania@bcm.tmc.edu

Pulmonary Pharmacology & Therapeutics
|June 20, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Authors' response.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Appropriate Use of Single Inhaled Triple Therapy in Uncontrolled Asthma: A Multinational Modified Delphi Consensus.

Journal of asthma and allergy·2026
Same author

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Lancet (London, England)·2026
Same author

Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.

The World Allergy Organization journal·2026
Same author

Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.

Chest·2026

Asthma management requires assessing more than just lung function (FEV(1)). This review offers guidance on alternative measures to ensure comprehensive asthma control and successful treatment outcomes.

Area of Science:

  • Pulmonology
  • Clinical Medicine

Background:

  • Asthma management guidelines recommend a stepwise approach based on symptoms and lung function (FEV(1)).
  • Normal lung function (FEV(1)) does not always correlate with a patient's daily activity limitations.
  • Relying solely on FEV(1) can lead to undertreatment in some asthma patients.

Purpose of the Study:

  • To provide practical guidance for the clinical assessment of asthma control.
  • To highlight the need for alternate assessment measures beyond pulmonary function tests.

Main Methods:

  • This is a review article.
  • The review synthesizes current understanding and clinical practices for asthma assessment.

Main Results:

  • Pulmonary function tests like FEV(1) are important but insufficient for assessing complete asthma control.

Related Experiment Videos

  • Limitations in daily activities despite normal FEV(1) indicate a need for further assessment.
  • Alternative assessment strategies are crucial for optimizing asthma management.

    • Conclusions:

    • Comprehensive asthma control assessment requires evaluating factors beyond FEV(1).
    • Clinicians should consider alternative measures to address daily activity limitations in asthma patients.
    • Effective asthma management necessitates a holistic approach to assessment and treatment.